Araştırma Makalesi

Ceranib-2 inhibits HIF1-α gene expression and induces apoptosis in HepG2 cells

Cilt: 45 Sayı: 4 27 Aralık 2020
Rumeysa Özyurt *, Mete Ozkurt , Abdullah Karadağ , Cemile Meral , Nılufer Erkasap
PDF İndir
TR EN

Ceranib-2 inhibits HIF1-α gene expression and induces apoptosis in HepG2 cells

Öz

Purpose: The aim of this study is to investigate the apoptotic effect of a novel anti-cancer drug, ceranib-2 and impact on HIF-1α levels on HepG2. Materials and Methods: The cell line was treated in vitro with 0,1, 1, 5, 10, 25 and 50 µM ceranib-2 for 24 and 48 hours and cell viabilitiy was determined. mRNA levels of acid ceramidase, caspase-3, caspase-8, caspase-9, Cyc1, HIF-1α and TNF-α were measured by qPCR. Results: Ceranib-2 at 10 µM concentration reduced the viability by about 58 % after 24 and 48 hours. The same dose increased mRNA level of caspase-3 and no change was detected on caspase-8 when compared to the control group after 24 hours. No difference was detected on caspase-3, but caspase-8 mRNA level increased after 48 hours with ceranib-2 at 10 µM concentration. Caspase-9 mRNA levels did not differ after 24 and 48 hours. Ceranib-2 at 10 µM concentration lowered mRNA level of Cyc1 against the control group after the 24- hour treatment. ASAH mRNA level was reduced after the 48-hour treatment with 10 µM ceranib-2. Reduction of ASAH indicated that 10 µM ceranib-2 could inhibit ceramidase after 48 hours and this may elavate ceramide concentration. TNF-α mRNA increased after 24 and 48 hours, but HIF-1α expression was low after 24 hours when compared to the control group. Conclusion: We have found that ceranib-2 induces apoptosis in HepG2, thus ceranib-2 may play an anti-cancer role at 10 µM concentration.

Anahtar Kelimeler

ceranib-2, apoptosis, HepG2

Destekleyen Kurum

This study was supported by a grant from the Eskisehir Osmangazi University Scientific Research Projects Committee (no: 2018-2023), Turkey.

Proje Numarası

no: 2018-2023

Kaynakça

  1. 1. Waller LP, Deshpande V, Pyrsopoulos N. Hepatocellular carcinoma: A comprehensive review. World J Hepatol. 2015;7(26):2648-63.

Kaynak Göster

APA
Özyurt, R., Ozkurt, M., Karadağ, A., Meral, C., & Erkasap, N. (2020). Ceranib-2 inhibits HIF1-α gene expression and induces apoptosis in HepG2 cells. Cukurova Medical Journal, 45(4), 1318-1325. https://doi.org/10.17826/cumj.702236
AMA
1.Özyurt R, Ozkurt M, Karadağ A, Meral C, Erkasap N. Ceranib-2 inhibits HIF1-α gene expression and induces apoptosis in HepG2 cells. Cukurova Med J. 2020;45(4):1318-1325. doi:10.17826/cumj.702236
Chicago
Özyurt, Rumeysa, Mete Ozkurt, Abdullah Karadağ, Cemile Meral, ve Nılufer Erkasap. 2020. “Ceranib-2 inhibits HIF1-α gene expression and induces apoptosis in HepG2 cells”. Cukurova Medical Journal 45 (4): 1318-25. https://doi.org/10.17826/cumj.702236.
EndNote
Özyurt R, Ozkurt M, Karadağ A, Meral C, Erkasap N (01 Aralık 2020) Ceranib-2 inhibits HIF1-α gene expression and induces apoptosis in HepG2 cells. Cukurova Medical Journal 45 4 1318–1325.
IEEE
[1]R. Özyurt, M. Ozkurt, A. Karadağ, C. Meral, ve N. Erkasap, “Ceranib-2 inhibits HIF1-α gene expression and induces apoptosis in HepG2 cells”, Cukurova Med J, c. 45, sy 4, ss. 1318–1325, Ara. 2020, doi: 10.17826/cumj.702236.
ISNAD
Özyurt, Rumeysa - Ozkurt, Mete - Karadağ, Abdullah - Meral, Cemile - Erkasap, Nılufer. “Ceranib-2 inhibits HIF1-α gene expression and induces apoptosis in HepG2 cells”. Cukurova Medical Journal 45/4 (01 Aralık 2020): 1318-1325. https://doi.org/10.17826/cumj.702236.
JAMA
1.Özyurt R, Ozkurt M, Karadağ A, Meral C, Erkasap N. Ceranib-2 inhibits HIF1-α gene expression and induces apoptosis in HepG2 cells. Cukurova Med J. 2020;45:1318–1325.
MLA
Özyurt, Rumeysa, vd. “Ceranib-2 inhibits HIF1-α gene expression and induces apoptosis in HepG2 cells”. Cukurova Medical Journal, c. 45, sy 4, Aralık 2020, ss. 1318-25, doi:10.17826/cumj.702236.
Vancouver
1.Rumeysa Özyurt, Mete Ozkurt, Abdullah Karadağ, Cemile Meral, Nılufer Erkasap. Ceranib-2 inhibits HIF1-α gene expression and induces apoptosis in HepG2 cells. Cukurova Med J. 01 Aralık 2020;45(4):1318-25. doi:10.17826/cumj.702236